Health Care

Insight into Heron Therapeutics’ CFO insider trade reveals confidence in its biochronomer drug‑delivery platform, highlighting operational discipline, market dynamics, and potential value‑based reimbursement gains.

Exozymes insider Korman Tyler Paz’s recent share purchase signals confidence in the biotech’s enzyme‑therapy pipeline, while RSU sales reduce future dilution.

Insider buying of Exagen Inc. signals confidence in its autoimmune testing pipeline, digital AI integration, and value‑based reimbursement strategy— a boost for niche diagnostic investors.

Executive chairman Matthew Rabinowitz’s 2026 insider buy‑sell pattern shows balanced liquidity management and confidence in Natera’s precision‑oncology growth.

Inside CFO Kelly Thomas Patrick’s 7,500‑share purchase shows confidence in a gene‑therapy firm amid sharp stock decline—why her buying matters for investors.

Beam Therapeutics insider buying trend: CEO Evans John M.’s recent 25k share purchase at $23.47 signals disciplined buying amid high buzz, but caution due to valuation concerns.

Insider sales by Penumbra’s President reveal a balanced buying trend amid a bullish run—signs of long‑term confidence, growth prospects, and strategic portfolio moves.

Julie Rubinstein’s disciplined insider trades show long‑term confidence in Adaptive Biotechnologies, balancing buy‑low/sell‑high strategy amid market shifts.

CEO Albert Bourla buys 20 phantom‑stock units at $29.58—showing long‑term confidence in Pfizer’s oncology pipeline and potential upside for investors.

CEO of ANI Pharma sells 5,400 shares, highlighting steady insider selling amid a 24% YTD decline – what it signals for the stock’s future.